Atlas Trials

A Study of Obinutuzumab (RO5072759) Induction in Patients With Relapsed/ Refractory Waldenström Macroglobulinemia, OBI-1

Clinical trial NCT03679455 · UNKNOWN

Trial details

NCT number
NCT03679455
Sponsor
Polish Myeloma Consortium
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Waldenstrom Macroglobulinemia
Start date
2018-09-21
Primary completion
2019-04-01
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.